Corcept's Miricorilant Shows Results In Treatment Of Non-Alcoholic Steatohepatitis; Phase 1b Study Demonstrates That Miricorilant, Effectively Reduces Liver Fat, Improves Liver Health And Key Metabolic And Lipid Measures And Is Well-Tolerated
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics Incorporated (NASDAQ:CORT) announced positive results from a Phase 1b study of its proprietary cortisol modulator, miricorilant, in patients with non-alcoholic steatohepatitis (NASH). The study found that patients who received 100 mg of miricorilant twice a week for 12 weeks experienced a 30% reduction in liver fat and improvements in liver enzymes and markers of liver disease. The company plans to initiate a Phase 2b trial in the fourth quarter.
July 17, 2023 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Corcept Therapeutics' positive Phase 1b study results for miricorilant in treating NASH could potentially boost investor confidence and the company's stock price in the short term.
Positive clinical trial results often lead to increased investor confidence, which can drive up a company's stock price. Given that Corcept Therapeutics is planning to initiate a Phase 2b trial in the fourth quarter, this suggests that the company is confident in the drug's potential, which could further boost investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100